Search

Your search keyword '"Gopal, Ajay"' showing total 1,547 results

Search Constraints

Start Over You searched for: Author "Gopal, Ajay" Remove constraint Author: "Gopal, Ajay"
1,547 results on '"Gopal, Ajay"'

Search Results

1. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

2. Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

3. Allogeneic Transplant and CAR-T Therapy After Autologous Transplant Failure in DLBCL: A Noncomparative Cohort Analysis

4. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer

5. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma

6. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

7. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

9. PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL.

11. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

12. Mitigating time toxicity in lymphoma and multiple myeloma.

16. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

19. Feasibility of a behavioral intervention using mobile health applications to reduce cardiovascular risk factors in cancer survivors: a pilot randomized controlled trial

22. Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study

23. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

24. Safety and Efficacy of Fully-Human-Binder-Bearing CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma after Failure of Murine-Binder-Bearing CD19 CAR T-Cell Therapy

25. Post-CAR-T Checkpoint Inhibition Can Result in Durable Responses in a Minority of Patients with Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL): Results of a Phase 2 Study of Nivolumab after CAR-T Failure

26. Identification and Prediction of Severe Hematologic Toxicity after CAR T-Cell Therapy Using Machine Learning-Based Time-Series Clustering

27. Identification of Predictors of CRS and Neurotoxicity Duration after Axicabtagene Ciloleucel Therapy

28. Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity

29. Data from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors

30. Supplementary Fig S2 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors

31. Supplementary Table S1 from Targeted Radiation Delivery before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-term Survivors

32. Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic

33. 90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma

34. Lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma: feasibility, safety and efficacy in a real-world setting

40. A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for Lymphoma.

41. Factors Associated with Prolonged CRS and Neurotoxicity after Treatment with Axicabtagene Ciloleucel

42. Targeted Radiation Delivery Before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-Term Survivors

43. Pembrolizumab with R-CHOP in Previously Untreated DLBCL: Sustained, High Efficacy and Safety with Long-Term Follow-Up

Catalog

Books, media, physical & digital resources